|
WO2021019350A1
|
|
Composition and methods for the treatment of anal and rectal disorders
|
|
WO2020144546A1
|
|
Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof
|
|
WO2020109957A1
|
|
Ophthalmic compositions and methods for the treatment of skin diseases and eye diseases
|
|
AU2019359520A1
|
|
Compositions and methods for the treatment of parkinson's disease
|
|
CA3110248A1
|
|
Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases
|
|
AU2019313484A1
|
|
Compositions and methods for the treatment of cancer
|
|
WO2020003051A1
|
|
Ophthalmic compositions and methods for the treatment of eye disorders
|
|
WO2019243970A1
|
|
Compositions and methods for the treatment of inflammatory skin diseases and cancer
|
|
EP3761970A1
|
|
Compositions and methods for the treatment of neurological diseases
|
|
KR20200118128A
|
|
Combination of antimuscarinic or anticholinergic and lipoic acid and uses thereof
|
|
KR20200089700A
|
|
Compounds, compositions and methods for the treatment of eye diseases and skin diseases
|
|
KR20200089292A
|
|
Compositions and methods for the treatment of eye diseases
|
|
AU2017365111A1
|
|
Compositions and methods for the treatment of fungal infections
|
|
SG11201810947PA
|
|
Compositions and methods for the treatment of cancer
|
|
WO2017221083A1
|
|
Compositions and methods for the treatment of viral infections
|
|
WO2017208088A2
|
|
Compositions and methods for the treatment of parkinson's disease
|
|
WO2018115984A1
|
|
Compositions and methods for the treatment of inflammation
|
|
CN110099681A
|
|
For treating the composition and method of xerostomia
|
|
CN110198707A
|
|
For treating the composition and method of oral diseases
|
|
US2019177267A1
|
|
Compositions and methods for the treatment of irritable bowel syndrome
|
